Valbenazine (Ingrezza): The First FDA-Approved Treatment for Tardive Dyskinesia.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it.

1. Comparative Analysis of Deutetrabenazine and Valbenazine as VMAT2 Inhibitors for Tardive Dyskinesia: A Systematic Review.Tremor and other hyperkinetic movements (New York, N.Y.) · 2024
   Pooled it
2. Assessing demographic and clinical characteristics and healthcare resource utilization of patients with schizophrenia with inadequate response to antipsychotic treatment.BMC psychiatry · 2026
   Article
3. Valbenazine for the Treatment of Chronic Motor or Vocal Tic Disorder (CMVTD).Cureus · 2025
   Article
4. Severe Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH) Following the Initiation of Valbenazine for Tardive Dyskinesia: A Case Report.Cureus · 2024
   Article
5. Structural mechanisms for VMAT2 inhibition by tetrabenazine.eLife · 2024
   Article
6. Risperidone Abruption-Induced Tardive Dyskinesia in a Six-Year-Old Male Patient With Known Autism and Attention Deficit Hyperactivity Disorder: A Case Report.Cureus · 2022
   Article
7. Therapeutic Strategies in Huntington's Disease: From Genetic Defect to Gene Therapy.Biomedicines · 2022
   Review
8. New Avenues for the Treatment of Huntington's Disease.International journal of molecular sciences · 2021
   Review
9. Valbenazine for the Treatment of Adults with Tardive Dyskinesia.Health psychology research · 2021
   Review
10. Antipsychotics for patients with pain.The Korean journal of pain · 2019
    Review

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract